![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GENELABS ANNOUNCES ISSUANCE OF U.S. PATENT ON DHEA COMPOSITION AND METHOD
GENELABS ANNOUNCES ISSUANCE OF U.S. PATENT ON DHEA COMPOSITION AND METHOD
June 12, 2006
Genelabs Technologies, Inc. announced today the issuance of U.S. patent No. 7,045,513 entitled "DHEA Composition and Method." The patent claims pharmaceutical formulations of
dehydroepiandrosterone, or DHEA, in certain purified polymorphic forms. DHEA is the active ingredient in Prestara, the company's investigational drug for systemic
lupus erythematosus, or lupus.
Yahoo
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct